Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies

Figure 1 Global prevalence of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than half of individuals with type 2 diabetes mellitus worldwide, with prevalence ranging between 55% and 70% in recent meta-analyses. Estimates vary by region, diagnostic modality, and population studied. MASLD is consistently associated with increased risk of advanced fibrosis, cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes. MASLD: Metabolic dysfunction-associated steatotic liver disease; MASH: Metabolic dysfunction-associated steatohepatitis.